The truth about the new class of Alzheimer’s drugs

You May Be Interested In:Israeli settlers beat U.S. citizen to death in West Bank


Illustration of amyloid plaques (orange) among brain cells

Science Photo Library/Alamy

In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.

The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…

share Paylaş facebook pinterest whatsapp x print

Similar Content

New Scientist. Science news and long reads from expert journalists, covering developments in science, technology, health and the environment on the website and the magazine.
What do GLP-1 drugs really tell us about the brain’s reward system?
Weight-Loss Drugs Like Ozempic Can Help Alcohol Addiction
Weight-Loss Drugs Like Ozempic Can Help Alcohol Addiction
4x4 Rims in Australia: Boost Your Off-Road Experience Now! - My Site
4×4 Rims in Australia: Boost Your Off-Road Experience Now! – My Site
What Americans Think Of The Biden Impeachment Inquiry
What Americans Think Of The Biden Impeachment Inquiry
Salma Hayek in This Cashmere Airport Outfit Is Going to Have You Rethinking a Certain Controversial Accessory
Salma Hayek in This Cashmere Airport Outfit Is Going to Have You Rethinking a Certain Controversial Accessory
Bella Hadid Cosigns the Ultimate Boho Coat That's Also Beloved by Taylor Swift
Bella Hadid Cosigns the Ultimate Boho Coat That’s Also Beloved by Taylor Swift
Streamline News | © 2024 | News